Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Martin Janičko
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02837939CT.gov Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Derived Transfer Factor (this asset) | Martin Janičko | P2/3 | CCC · 55 |
| Empagliflozin | Yale University | P4 | BB |
| Avatrombopag | Tongji Hospital | P4 | BB |
| Pentoxifylline | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Erythropoietin | Institute of Liver and Biliary Sciences, India | P3 | BB |
| Sodium Tetradecyl Sulfate | Kaohsiung Veterans General Hospital. | P3 | B |
| Everolimus | Azienda Ospedaliera di Padova | P2 | B |
| Acetylcysteine | Azienda Ospedaliera di Padova | P2 | B |
| Amino Acids, Branched-Chain | Louisiana State University Health Sciences Center in New Orleans | P2 | CCC |
+16 more in the Liver Failure cohort
Other indications for Human Derived Transfer Factor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P2/3 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Derived Transfer Factor in Liver Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-derived-transfer-factor-liver-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →